To The Moon

HIMS Is Quietly Building a Category Most People Don’t Understand $Hims & Hers Health Inc.(HIMS)$ might be sitting on its biggest catalyst yet — but the market hasn’t fully connected the dots. If the U.S. Food and Drug Administration actually follows through on reevaluating restricted peptides (as hinted by Robert F. Kennedy Jr.), this could quietly unlock a massive new market. Peptides are booming in the US ! HIMS distribution and social could be a massive upside here. You must have conviction ! Peptides are short chains of two or more amino acids linked by covalent (peptide) bonds, acting as fundamental building blocks for proteins and serving as crucial cell-signaling molecules. They are generally smaller than proteins, typically consisting of 2 to 50 amino acids. Peptides occur naturally, regulating body functions (e.g., insulin), and are used therapeutically for weight loss, skin anti-aging, and muscle repair. Usage Examples of Peptides Peptides have diverse applications in health, skincare, and medicine: Skincare & Anti-Aging: Peptides like GHK-Cu are used in serums to boost collagen, improving skin firmness, reducing wrinkles, and encouraging hair growth. Therapeutic Medications: Synthetic peptides mimic natural hormones to treat conditions, such as semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss and diabetes. Supplementation: Collagen peptides are used to support bone mineral density and potentially repair muscle. Biological Signaling: They act as neurotransmitters, immune modulators, and hormones (e.g., oxytocin). Right now, peptides live in a strange place: Huge demand Limited regulation Mostly gray market If even part of that shifts into regulated channels, the winners won’t be random labs — it’ll be companies that already have: Distribution Manufacturing Subscription infrastructure That’s where Hims & Hers Health stands out. They’ve already: Built a scaled DTC health platform Invested in peptide manufacturing Proven they can monetize “protocol-based” treatments The real opportunity isn’t hype — it’s structure. Think about it: A simple peptide protocol at $150–300/month → 200k users = $300M+ ARR And that’s just one vertical. Now layer in: Existing GLP-1 momentum Expanding global footprint High-margin compounding model But here’s the nuance most people are missing: If regulation improves → trust increases → adoption scales. This isn’t just about “selling peptides.” It’s about legitimizing an entire category that already has demand. Meanwhile: ~30% short interest Stock still far below highs Sentiment anchored in the past If fundamentals inflect and regulatory risk declines, the setup becomes asymmetric. This only works if policy actually shifts. But if it does, $HIMS isn’t chasing the market — it’s already built for it. Sometimes the biggest opportunities aren’t new ideas… they’re existing demand finally becoming legal. @TigerStars @Tiger_comments @Daily_Discussion @TigerObserver @TigerPM